Plano, Texas (PRWEB)
May 26, 2017
Amir Qureshi, MD is the first physician in Arkansas to implant Nuvecta’s Algovita® Spinal Cord Stimulation System, a powerfully versatile, patient-centric spinal cord stimulation system. The Nuvectra™ Algovita SCS System has been FDA approved as a treatment option for chronic intractable pain.
“We are pleased to be the first in Arkansas to introduce the most powerful SCS system and the only stretchable lead on the market. This technology gives quality of life back to chronic pain patients” said Dr. Qureshi regarding the Nuvectra Algovita system.
Chronic pain affects over 100 million Americans according to the Institute of Medicine, more than diabetes, cancer, and heart disease combined. Chronic pain is difficult to treat, but one potential treatment option is spinal cord stimulation, or SCS. SCS works by masking or interrupting pain signals as they travel up the spinal cord to the brain. A small, rechargeable battery is implanted under the patient’s skin and connected to thin wires, called leads, which stimulate the nerves sending pain signals. The stimulation “overrides” the pain signals, and instead of feeling pain, patients may feel a tingling sensation known as paresthesia.
The Algovita SCS System is a new offering to the SCS market, featuring 24 current sources and the broadest overall set of parametric ranges offered for tonic SCS. This combination provides flexible coverage and expanded programming options for individualized patient therapy. Algovita also offers the industry’s only stretchable leads, which are designed to reduce the risk of lead fracture and migration. In addition, the systems percutaneous leads feature up to 12 contacts for wide coverage of potential pain areas. The…